Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

SARS-CoV-2 델타 변이형 감염 고위험 환자의 질병 중증도 결과에 대한 카시리비맙-임데비맙 치료의 의심스러운 임상 이점

Published on
Journal: European journal of internal medicine
[저자] Noah Shopen, Michal Dekel, Michal Mizrahi, Efrat Zandberg, Daniel Talmud, Neta Cohen, Tel Aviv Sourasky Medical Center Emergency Department study group
[Category] COVID19(2023년), SARS, 변종, 진단,
PMC URL    [DOI] 10.1016/j.ejim.2022.03.001    
[Article Type] Article
[Source] PMC

No abstract available
Keywords: BNT162b2 vaccine; Casirivimab/Imdevimab therapy; High-risk patients; SARS-CoV-2 delta variant; Severe outcome.

All Keywords
【저자키워드】 BNT162b2 vaccine, SARS-CoV-2 Delta variant, Casirivimab/Imdevimab therapy, High-risk patients, severe outcome, 【초록키워드】 BNT162b2 vaccine, outcome, BNT162b2, Casirivimab, Imdevimab, High-risk patients, Abstract, SARS-CoV-2 delta, 【제목키워드】 Treatment, disease severity, variant, Infection, outcome, clinical benefit, SARS-CoV-2 delta, high-risk patient,
사용 가능한 초록 없음 {{ 키워드: }} BNT162b2 백신; 카시리비맙/임데비맙 요법; 고위험 환자; SARS-CoV-2 델타 변이체; 심각한 결과입니다.